Browse the evidence

Maintaining Hemoglobin A1c (HbA1c) levels below 6.0% is a critical intervention for preventing the onset and progression of coronary atherosclerotic heart disease (CHD).

To lower your risk of heart disease, aim to keep your HbA1c below 6%. This involves eating a healthy diet, reducing calories if overweight, and getting at least 150 minutes of moderate exercise per week. Regular screening is essential to catch prediabetes early.

GLP-1 receptor agonists (semaglutide, tirzepatide) cause rapid, significant loss of facial and body subcutaneous fat, leading to skin laxity, volume loss, and accelerated facial aging that requires proactive, multimodal aesthetic intervention.

If you are taking Ozempic or Mounjaro, expect your face to lose volume and your skin to sag. Don't wait until you look 'old' to act. Start aesthetic treatments (like fillers or skin tightening) early in your weight loss journey to maintain your shape and youthfulness.

A structured, multimodal aesthetic intervention protocol (fillers, RF, HIFU, collagen stimulators) initiated early in GLP-1 therapy mitigates facial volume loss and skin laxity.

Work with a cosmetologist to create a personalized plan. Use fillers for volume, RF/HIFU for tightening, and collagen stimulators for skin quality. Start early, not after you've lost all the weight.

GLP-1 receptor agonists (e.g., semaglutide) can support sustained weight stability and may be safely restarted postoperatively in body contouring patients.

If you are using GLP-1 agonists like semaglutide for weight loss, discuss with your doctor whether it is safe to restart or continue them after body contouring surgery. They can help maintain your weight stability and support long-term results.

Adding Subetta® (affinity-purified antibodies against the insulin receptor beta-subunit) and cholecalciferol (Vitamin D) to standard therapy significantly improves glycemic control, lipid profiles, and reduces body mass index in elderly women with type 2 diabetes compared to standard therapy alone.

For elderly women with Type 2 Diabetes who are struggling with weight gain and high blood sugar despite standard medication, adding Vitamin D (4000 IU daily after a loading phase) and Subetta® to their existing regimen (Metformin/Gliclazide) can significantly improve blood sugar, cholesterol, and weight loss without causing dangerous low blood sugar episodes.

Early intensive intervention targeting stringent glycaemic control (HbA1c ≤ 6.5%) and significant weight loss (≥10%) at diagnosis improves long-term prognosis and prevents microvascular complications in younger patients with longer life expectancy.

If you are diagnosed with Type 2 Diabetes and are under 65, do not accept a standard HbA1c target of 7% as the end goal. Work with your doctor to aim for a stricter target (≤ 6.5%) and significant weight loss (10% or more) immediately. This early, intensive approach is critical for preventing long-term complications like eye and kidney damage, especially given your longer life expectancy.

GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors are preferred first-line treatments for patients with Type 2 Diabetes and obesity or cardiovascular disease, respectively, due to their weight-reducing and cardioprotective properties.

If you have Type 2 Diabetes and obesity or heart disease, ask your doctor about GLP-1 receptor agonists or SGLT2 inhibitors. These drugs not only help control blood sugar but also promote weight loss and protect your heart, making them preferred choices over metformin alone for many patients.

Adding luseogliflozin (an SGLT2 inhibitor) to incretin modulator therapy produces an additive glucose-lowering effect, specifically reducing time above range, with the magnitude of benefit being significantly greater in patients consuming high-carbohydrate diets compared to low-carbohydrate diets.

If you are taking an incretin-based diabetes medication (like a GLP-1 agonist or DPP4 inhibitor) and consume a diet high in carbohydrates (e.g., >180g carbs daily), adding luseogliflozin (2.5mg daily) may provide better blood sugar control than adding it to a low-carb diet. This combination appears to work additively, meaning the drugs complement each other to handle the glucose load from carbs more effectively than either might alone in that specific context.

A remotely delivered, 12-month GLP-1RA (semaglutide) supported weight management program achieves significant weight loss (mean 19.1% of starting weight) in participants who maintain an active subscription, but high withdrawal rates (60.4%) limit generalizability.

If you have obesity and are considering a GLP-1RA like semaglutide, a remote program can help you lose significant weight (around 19% on average) if you stick with it. However, be aware that many people drop out, often due to side effects or cost. To succeed, you need to be committed to the weekly injections and the digital support, and understand that stopping the medication likely leads to weight regain.

Tirzepatide produces significantly greater long-term total body weight loss and fat mass reduction compared to Semaglutide in real-world clinical practice, with effects becoming distinct after 6 months.

If you are choosing between Semaglutide and Tirzepatide for long-term weight management, Tirzepatide offers significantly greater weight loss after 12 months. To maximize results and protect your muscle, you must combine the medication with a program that includes strength training twice a week and a protein intake of 60-90 grams daily.

Females experience significantly greater weight loss than males when treated with incretin-based obesity medications (Semaglutide and Tirzepatide).

If you are male, expect that your weight loss may be slower than that of female peers taking the same medication. This is a known biological response. Do not be discouraged; the medication still provides significant metabolic benefits and fat loss, even if the scale moves slower.

GLP-1 analogues (Semaglutide and Liraglutide) are recommended for MASLD patients with BMI >27 kg/m2 and CVD risk factors when lifestyle intervention is insufficient, offering significant weight loss and CVD risk reduction.

If lifestyle changes alone haven't reduced your weight or CVD risk, and your BMI is above 27, ask your doctor about GLP-1 analogues like Semaglutide or Liraglutide. These medications can help you lose significant weight (up to 15% with Semaglutide) and improve your heart health.

The dual GLP-1R/GCGR agonist BI 456906 produces clinically meaningful body weight loss (up to 13.8% over 16 weeks) in adults with overweight/obesity, driven by target engagement at both receptors.

BI 456906 is a once-weekly injection for people with overweight or obesity that works by targeting two hormones (GLP-1 and Glucagon). In early studies, it led to significant weight loss (nearly 14% over 4 months). The main side effects are gastrointestinal (nausea, vomiting), which are common but often manageable. It is designed for people who may not achieve sufficient weight loss with single-target therapies.

In patients with type 2 diabetes duration greater than 10 years, GLP-1RA plus basal insulin fixed-ratio combinations (iDegLira, iGlarLixi) may be numerically more effective for HbA1c reduction than tirzepatide, suggesting tirzepatide is better suited for early-stage disease.

For patients with type 2 diabetes for more than 10 years, GLP-1RA plus basal insulin fixed-ratio combinations may offer better glycemic control than tirzepatide alone, making them a strong option for long-standing disease.

Withholding GLP-1 receptor agonists for at least three half-lives before elective surgery is recommended for weight management patients to minimize retained gastric contents.

For weight loss patients: Check the half-life of your specific drug (e.g., Semaglutide ~7 days, Dulaglutide ~5 days). Stop taking it at least 3 times that duration before your scheduled surgery. For example, if you take Semaglutide (7-day half-life), stop at least 21 days before surgery. Consult your doctor for a bridge plan for blood sugar if applicable.

For patients with Type 2 Diabetes, prolonged cessation of GLP-1 receptor agonists may worsen peri-operative glycaemic control, requiring individualized management and endocrinologist consultation.

If you have Type 2 Diabetes, do not simply stop your GLP-1 drug without a plan. Stopping it can cause your blood sugar to rise dangerously high during surgery. You need a personalized plan from your doctor and likely an endocrinologist to manage your sugar levels during the period you are off the drug.

GLP-1 agonists (specifically liraglutide and exenatide) induce significant weight loss in patients with antipsychotic-induced weight gain (AIWG) without worsening psychiatric symptoms.

For patients gaining weight from antipsychotics, GLP-1 agonists like liraglutide or exenatide are effective tools for weight loss. Liraglutide shows stronger results (-4.7 kg) than exenatide (-2.5 kg). These drugs do not worsen mental health symptoms, making them safe adjuncts to antipsychotic therapy. Side effects like nausea are common but usually manageable.

Individual metabolic and hormonal adaptations, including somatotype-specific responses and adaptive thermogenesis, drive significant variability in weight management outcomes, rendering the 'calories in, calories out' model insufficient for personalized strategies.

Stop assuming that a calorie is just a calorie for everyone. Your body's hormonal and metabolic response to food and restriction is unique. To succeed, you need to move beyond simple calorie counting and consider personalized strategies like precision nutrition, which may involve analyzing your metabolic profile, hormonal status, and even genetic factors to tailor your diet and exercise.

Somatotypes (ectomorph, mesomorph, endomorph) correspond to distinct metabolic and hormonal profiles that influence individual responses to diet and exercise, suggesting tailored interventions are more effective.

Understand your body type as a starting point for tailoring your approach. Ectomorphs may need high-protein and resistance training to preserve muscle. Mesomorphs may respond well to balanced macronutrients and strength training. Endomorphs may benefit from low-GI diets and stress management to modulate insulin and cortisol. Use this framework to personalize your strategy.

Semaglutide treatment resolves prediabetes and normalizes HbA1c levels in post-bariatric patients, even in those who did not achieve full diabetes remission post-surgery.

If you had bariatric surgery and still have prediabetes, semaglutide can help normalize your blood sugar levels. In this study, all patients with prediabetes who took semaglutide for a year achieved normal glucose levels. This highlights the importance of ongoing metabolic management after surgery.

GLP-1 receptor agonists (GLP-1 RAs) improve sperm parameters (concentration, motility, morphology) and testosterone levels in obese men with metabolic hypogonadism, primarily through weight loss and direct testicular effects.

If you are obese and struggling with fertility, GLP-1 medications like semaglutide or liraglutide may help improve your sperm count and testosterone levels, not just by helping you lose weight, but potentially by directly supporting testicular function. The key is working with a doctor to start with a low dose and slowly increase it to minimize stomach issues. While these drugs are expensive, the potential for improved fertility and sustained weight loss might justify the cost compared to other treatments.

Semaglutide administration (up to 1 mg weekly) produces significant weight and BMI reduction in obese patients with kidney failure undergoing dialysis, with a side effect profile comparable to non-dialysis populations.

If you are on dialysis and obese, semaglutide injections (starting at 0.25mg and increasing to 1mg weekly) can help you lose significant weight (average 4.6kg in 12 weeks) with manageable side effects like mild nausea. This weight loss may allow you to qualify for kidney transplantation, which offers better survival and quality of life than remaining on dialysis. Consult your nephrologist about this off-label use.

Myostatin acts as a negative regulator of muscle hypertrophy and cardiac pathological hypertrophy, and its inhibition or reduction through exercise can promote muscle growth and protect against certain cardiac dysfunctions.

Consistent exercise naturally lowers myostatin, a protein that limits muscle growth. This is one reason why regular resistance training is effective for building muscle.

Tirzepatide, a dual GLP-1/GIP receptor agonist, promotes significant weight loss and improves metabolic parameters in obese patients with PCOS, potentially offering superior tolerability compared to GLP-1R agonists alone due to its imbalanced receptor affinity.

For obese individuals with PCOS, tirzepatide is a once-weekly injection that helps with weight loss and blood sugar control. It works by mimicking hormones that regulate appetite and insulin. While it can cause stomach upset, the dual-action design might make it easier to tolerate than older drugs. It is not a substitute for lifestyle changes but can be a powerful tool when combined with diet and exercise.